Patents Represented by Attorney Randolph N. Mohr
  • Patent number: 8119604
    Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: February 21, 2012
    Assignee: Immunex Corporation
    Inventors: Wayne R. Gombotz, Richard L. Remmele, Jr.
  • Patent number: 8101184
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: January 24, 2012
    Assignee: Amgen Inc.
    Inventors: Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards
  • Patent number: 7968313
    Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: June 28, 2011
    Assignee: Amgen Inc.
    Inventors: Jeffrey T. McGrew, Allison A. Bianchi
  • Patent number: 7700722
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: April 20, 2010
    Assignee: Amgen Inc.
    Inventors: Bruce Kerwin, Byeong Chang, Lei Shi
  • Patent number: 7691605
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: April 6, 2010
    Assignee: Immunex Corporation
    Inventors: Jeffrey T. McGrew, Allison A. Bianchi
  • Patent number: 7569387
    Abstract: Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: August 4, 2009
    Assignee: Amgen Inc.
    Inventors: Lars Eyde Theill, Richard Yeh, Scott Michael Silbiger, Gang Yu, Giorgio Senaldi
  • Patent number: 7381545
    Abstract: The invention relates to the use of a phosphate glass as a phosphorous source in the media of high cell density bacterial fermentation processes in order to reduce metallophosphate precipitation reactions. The methods of the invention demonstrate a practical method for controlling levels of metallophosphate precipitation in both the nutrient media and the fermentor which also result in increased cell densities and are useful in a variety of high cell density bacterial fermentation processes.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: June 3, 2008
    Assignee: Amgen Inc.
    Inventors: Craig Eric Curless, Jeffrey Burke Baclaski
  • Patent number: 7118884
    Abstract: The invention relates to the use of a phosphate glass as a phosphorus source in the media of high cell density bacterial fermentation processes in order to reduce metallophosphate precipitation reactions. The methods of the invention demonstrate a practical method for controlling levels of metallophosphate precipitation in both the nutrient media and the fermentor which also result in increased cell densities and are useful in a variety of high cell density bacterial fermentation processes.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: October 10, 2006
    Assignee: Amgen Inc.
    Inventors: Craig Eric Curless, Jeffrey Burke Baclaski
  • Patent number: 6774106
    Abstract: This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3's binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: August 10, 2004
    Assignee: Amgen Inc.
    Inventors: Lars Eyde Theill, Gang Yu
  • Patent number: 6770746
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: August 3, 2004
    Assignee: Amgen Inc.
    Inventors: Colin Gregg, Olaf Kinstler
  • Patent number: 6632638
    Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with Uracil DNA glycosylase inhibitor (UGI).
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: October 14, 2003
    Assignee: Amgen, Inc.
    Inventors: Marshall Snavely, Lana Klionsky
  • Patent number: 6596852
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: July 22, 2003
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Patent number: 6489130
    Abstract: The invention is directed to purified and isolated novel DAKAR (death associated kinase containing ankyrin repeat) polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides and the uses of the above.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: December 3, 2002
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, G. Duke Virca